

PCCP

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Synthesis and Characterization of Octaarginine Functionalized**
2 **Graphene Oxide Nano-carrier for Gene Delivery Applications**

3
4 **Rana Imani^{†,‡}, Shahriar Hojjati Emami^{†,*}, Shahab Faghihi^{‡,*}**

5
6 [†]*Department of Biomedical Engineering, Amirkabir University of Technology,*

7 *Tehran15875/4413, Iran*

8 [‡]*Tissue Engineering and Biomaterials Division, National Institute of Genetic Engineering and*

9 *Biotechnology, Tehran 14965/161, Iran*

10

11

12

13

**Corresponding author:* Biomedical Engineering Department, Amirkabir University of Technology, Tehran 15875, Iran.

Tel.: +98 21 6454 2367; fax: +98 21 6646 8186.

E-mail address: semami@aut.ac.ir

**Corresponding author:* Tissue Engineering and Biomaterials Division, National Institute of Genetic Engineering and Biotechnology, Tehran 14965/161, Iran.

Tel.: +98 21 44580386; fax: +98 21 44580386.

E-mail address: sfaghihi@nigeb.ac.ir, shahabeddin.faghihi@mail.mcgill.ca (S. Faghihi).

1 Abstract

2 The success of gene therapy is largely dependent on development of a gene carrier. Recently
3 cell-penetrating peptides (CPPs) have been employed for enhancing gene and drug delivery
4 efficacy of nano-particles. The feasibility of octaarginine (R8) functionalized graphene oxide
5 (GO) as a novel nano-carrier for gene delivery is investigated. DNA plasmid expresses enhanced
6 green fluorescence (pEGFP) is used as a model gene to study the R8-GO transfection ability into
7 mammalian cells. Different ratios of R8 peptide (0.1-1.5 μmol per mg of GO) is conjugated to
8 carboxylated graphene oxide by two steps amidation process. The process of peptide conjugation
9 is analyzed by Fourier transform infrared (FTIR), atomic force microscopy (AFM), Uv-vis
10 spectroscopy and X-ray diffraction (XRD). In order to obtain the highest transfection of pEGFP
11 into the cells, the amount of bonded peptide to GO is optimized which is evidenced by dynamic
12 light scattering (DLS), zeta potential, TNBS and gel retardation assays. The cytotoxicity of R8-
13 functionalized GO is also tested by MTT assay. The results confirm the successful attachment of
14 R8 peptide to GO. The AFM and XRD results show significant increase in thickness of nano
15 graphene oxide sheets (NGOS) from 0.8 to 2-7 nm as well as an increase in GO interlying space
16 after R8-functionalization process. A reduction in nano-carriers stability in both aqueous solution
17 and cell culture media are observed when the amount of peptide increased more than 1 $\mu\text{mol}/\text{mg}$.
18 Gel electrophoresis analysis shows the highest DNA loading on the peptide functionalized GO at
19 the ratios of 0.5 and 1 $\mu\text{mol}/\text{mg}$. As the result, the 1 $\mu\text{mol}/\text{mg}$ of conjugated peptide sample
20 shows the highest conjugational efficiency and EGFP gene expression along with improved
21 dispersibility and biocompatibility. Overall, the findings reveal the importance of peptide density
22 on the surface of NGOS in order to obtain the most efficient cell transfection. It is concluded that
23 the R8-conjugated GO could be a promising delivery nano-carrier for gene delivery with
24 relevancy in the biotechnology therapeutics and clinical applications.

25 **Keywords:** Gene therapy; Nano-carrier, Graphene oxide; Cell penetrating peptide; Octaarginine.

26
27
28
29
30
31
32
33
34

1- Introduction

To have a successful gene therapy a carrier that efficiently delivers nucleic acids into the cells is commonly required^{1,2}. One major obstacle that impedes a successful transfection of nucleic acid molecules is the development of a simple, safe, and efficacious delivery system. An ideal gene delivery carrier must compact genetic materials into nano-sized particles that are colloiddally stable, protect nucleic acids from enzymatic degradation, effectively transit nucleic acids to target cells, and achieve a significant transfection yield³.

In recent years, nanotechnology has revolutionized medical treatments and therapies particularly by gene delivery⁴. Various nano-materials with unique physical and chemical properties have been used in the field such as carbon-based materials^{5,6}. Graphene, a single layer of carbon atoms in a closely packed honeycomb two-dimensional structure, is a new kind of carbon nanostructure material which attracted many attentions⁷. Graphene and its derivatives such as graphene oxide (GO) possess unique characteristics including high water dispersibility, good colloidal stability, tunable surface, and good biocompatibility⁸. The abundant oxygen functional groups on the basal plane and edges of GO can be used as anchoring sites for bio-functionalization purposes (Schematic. 1a). These attributes make the GO more attractive and potent candidate rather than other nano-carriers⁹. In particular, the use of GO as a potential vehicle for targeted delivery of drugs and genes in cancer therapy has attained considerable interest¹⁰. Duo to the inherent negative charge of GO sheets, for an efficient gene delivery it is necessary to modify its surface in order to achieve effective loading of negatively charged genetic components such as plasmid DNA (pDNA), short interference RNA (siRNA), etc. A practical strategy to accomplish such complexion that enhances transfection ability of GO with no cytotoxic effect, could be incorporation of cationic molecules as a linker into the surface of GO¹¹.

Reports have explored the efficacy of various surface functionalization methods in order to improve the carrier ability of GO. Dai and colleagues have demonstrated that polyethylene glycol functionalized GO is able to deliver aromatic, water-insoluble anticancer drugs into cells¹². The application of graphene as a transporter to deliver oligonucleotides for gene detection and therapy has been reported in few studies¹³⁻¹⁵. Feng et al. have successfully performed physical complexion of different molecular weights of polyethyleneimine (PEI) with GO as a nano-vehicle for gene transfection¹⁶. In the other studies, Kim et al. and Chen et al. have developed a GO-based gene delivery system by covalent conjugation of branched PEI to GO nano-sheets^{13,17}. Chitosan (CS) as a positively charged biopolymer has been utilized by Le and his co-workers to improve surface functionality of GO. They have shown that the GO-CS nano-carrier is able to carry and deliver both anticancer drugs and genes¹⁸. The polyethylene glycol conjugation along with π - π stacked pyrenemethylamine have been employed for surface functionalization of GO to deliver siRNA to cancer cells¹⁹.

Recently, cell penetrating peptides (CPPs) have gained much attention due to their ability to translocate drugs, genes, and large therapeutic molecules intracellularly²⁰. CPPs are short strands of arginine and/or lysine-rich peptides (<30 amino acids) that use their cationic nature for efficient intracellular accumulation. It has been reported that these kinds of peptides may enhance cellular uptake owing to their strong tendency for cell adherence, without any dependency on receptors, temperature, nor an energy-dependent pathway²¹. One such example is arginine (R) rich CPP like TAT peptide (derived from the HIV-1 protein) or octararginene (R8). These peptides are small, highly cationic and have the ability to cross the plasma

1 membrane of eukaryotic cells²². Among all the polyarginine peptides, the R8 (Schematic. 1b)
2 has shown the highest cellular uptake while R6 and R9 presented optimum translocation through
3 cell membrane²³. It is shown that the transduction efficacy of different nano-particles or
4 biomolecules (e.g. proteins, nucleic acids) into cells can be improved using R8 peptide because
5 of its natural based composition and low cytotoxicity²⁴. While much research has been devoted
6 to the functionalization of nano-particles with R8 peptide for variety of applications there has
7 been no investigation on R8-conjugated GO nano-sheets as a potential gene carrier.

8 In this study, a novel CPP-conjugated GO, as gene carrier system was strategically designed
9 and prepared. We aimed to improve the transfection efficiency of nano-graphene oxide sheets
10 (NGOS) by R8 conjugation while maintaining a low cytotoxicity. The effect of conjugation ratio
11 (R8 to GO) on the surface charge, particle size, morphology, and DNA complexation ability of the
12 nano-carriers was also investigated. The optimized nano-carrier formulation was achieved after a
13 precise chemical, physical and biological characterization.

14 **2. Materials and methods**

15 *2.1. Materials*

16 All chemical materials involved in GO synthesis were purchased from Aldrich (Japan).
17 Octaarginine was obtained from GL Biochem LTD (Shanghai). DMEM culture medium, fetal
18 bovine serum (FBS), Trypsin, MTT solutions and phosphate buffer solution were all purchased
19 from GIBCO (UK). The L929 fibroblast and HEK cell lines were obtained from American Type
20 Culture Collection (ATCC, Manassas, VA, USA). Plasmid DNA encoding enhanced green
21 fluorescent protein (pEGFP) was purchased from Invitrogen (USA). Sodium bicarbonate,
22 sodiumdodecyl sulfate (SDS) and 2,4,6-Trinitrobenzene sulfonic acid (TNBS) used for TNBS
23 assay were purchased from Merck (Germany).

24 *2.2. Methods*

25 *2.2.1. Preparation of nano-graphene oxide sheets (NGOS)*

26 The NGOS was prepared based on a modified Hummer method²⁵. In a typical experiment,
27 natural graphite powder (1 gr) was suspended in 120 ml of sulfuric acid (98%). The mixture was
28 cooled in an ice bath followed by addition of NaNO₃ (500 mg) under moderate stirring (200
29 RPM). After 60 min KMnO₄ (6 gr) was added and the mixture was heated to reach 35 °C under
30 constant stirring condition. After 48 hours, the brownish green solution became too viscose to
31 stir. Double distilled water (DDW) was slowly added to the reaction to keep the temperature at
32 70 °C for one hour. Finally, 30% H₂O₂ (10 ml) was added to the mixture until the color was
33 changed to bright yellow. The mixture was rested for 2 days to precipitate GO nano-sheets. The
34 supernatant was removed and precipitated powder was washed ten times with 0.5 M aqueous
35 HCl to remove metal ions followed by washing with DDW to remove the acid residues. To
36 achieve nano-sized mono layer GO sheet, the suspension was dispersed by probe-typed
37 ultrasonic treatment (200 W, 2h). The resultant brown solution was freeze dried to obtain a fine
38 nano-graphene oxide powder.

39 *2.2.2. Carboxylation of nano-graphene oxide sheets (NGOS-COOH)*

40 Carboxylic acid functionalized nano-graphene oxide sheets (NGOS-COOH) was obtained
41 through reaction with chloroacetic acid under strong basic conditions to transform the hydroxyl,
42 epoxide, and ester groups into carboxylic acid (COOH) moieties. The carboxylation process was
43 performed under optimized condition based on our previous study. Briefly, 1mg of NGOS was

1 dispersed in deionized water (1ml) under probe-type sonication (100W, 30 min) to obtain a clear
2 solution. Chloroacetic acid solution in 4M NaOH was prepared and the NGOS aqueous
3 suspension was immediately added to the final concentration of 0.2 mg/ml. The suspension was
4 reacted for 75 min (or 12h) under bath-sonication at room temperature to transform -OH groups
5 to -COOH via conjugation of acetic acid moieties. The NGOS-COOH solution was centrifuged
6 and washed five times with DDW and transferred to a dialysis bag. After dialysis against DDW
7 to remove the excess reactant, a well dispersed NGOS-COOH aqueous solution was obtained.

8 2.2.3. Peptide conjugation

9 The synthesized nano-carrier (NGOS-COOH) was functionalized by octaarginine peptide
10 sequence (R8) through two steps diimide-activated amidation under ambient conditions²⁶. In the
11 first step, 10 mg of NGOS-COOH was suspended in 10 mL of deionized water by sonication of
12 the mixture for 1 h. Subsequently, 5 mL of a 500 mM MES buffer solution (pH ~ 6.1) and 5 mL
13 of a 50 mg/ mL NHS aqueous solution were added to the above mentioned suspension. After 15
14 min of fast stirring, 6 mL fresh EDAC aqueous solution (10 mg/mL) was added to the mixture at
15 room temperature. After 30 min stirring the suspension was centrifuged and rinsed thoroughly
16 with 50 mM MES buffer solution (pH ~ 6.1) to remove excess reactants. In the second step, the
17 esterated nano-sheets were re-dispersed in 5 mL of 50 mM MES buffer solution (pH ~ 6.1) and
18 1mL of R8 in MES buffer solution (pH ~ 6.1) was added to the mixture. After shaking the
19 mixture on a platform shaker (150 rpm) at room temperature for 24 h, the suspension was
20 centrifuged and washed with MES buffer solution to remove unbound proteins. The peptide
21 functionalized nano-sheets were dispersed in deionized water for further measurements. A series
22 of peptide-NGOS complexes was obtained using various R8:NGOS ratios ($\mu\text{mol}:\text{mg}$) consists of
23 0.1, 0.5, 1 and 1.5. The samples were called GOP0.1, GOP0.5, GOP1 and GOP1.5, respectively.

24 2.3. Nano-carriers characterization

25 2.3.1. Instrumentation

26 The samples including NGOS, NGOS-COOH, and R8-functionalized NGOS were pressed
27 into the potassium bromide pellets and examined with Fourier transform infrared (FTIR)
28 spectrophotometer within the range of $3600\text{--}500\text{ cm}^{-1}$ at a resolution of 4 cm^{-1} (German Nicolet
29 FTIR Nexus-670 IR). Uv-vis absorption spectra of the samples were also obtained using a
30 Neosys-2000, Scinco Co. Ltd., Korea spectrophotometer at room temperature. The size and
31 morphology of NGOS, NGOS-COOH and R8-NGOS samples deposited from a dilute aqueous
32 dispersion (0.01mg/ml) on a freshly cleaved mica were determined by an atomic force
33 microscope (AFM, Nanoscope III Multimode, VEECO) in tapping mode and transmission
34 electron microscope (TEM, Philips169 CM200 200 kV). The X-ray diffraction (XRD) analysis
35 of the samples was performed using a diffractometer (EQUINOX300, Inel, France) at 2θ ranging
36 from 5° to 40° using $\text{CuK}\alpha$ radiation (40kV, 100mA). Finally, zeta potential of the samples
37 (0.01mg/ml, pH 6.1) as well as hydrodynamic size distribution were measured using a Zetasizer
38 Nano-ZS-90 (Malvern Instruments, UK).

39 2.3.2. TNBS assay

40 For quantification of attached R8 peptides to graphene nano-sheets' surface a colorimetric-
41 based assay was used which employed 2,4,6-Trinitrobenzene sulfonic acid (TNBS, Thermo
42 Scientific Pierce). The R8 peptide solutions were first used to produce a standard curve for
43 quantification of R8 binding onto the graphene nano-sheets. In brief, 0.5 mL TNBS in 0.1 M

1 sodium bicarbonate (pH 8.5, 0.01%, w/v) was added to 1 mL of R8 solutions having different
2 concentrations (10 to 100 $\mu\text{g}/\text{mL}$). The mixtures were then incubated at 37 $^{\circ}\text{C}$ for 2 h followed
3 by the addition of 0.5 mL of 10% sodiumdodecyl sulfate (SDS) and 0.25 mL of 1 M HCl to each
4 solution. The absorbance was read at 335 nm and plotted against R8 concentration for each
5 sample. After the addition of peptide conjugated samples (0.5 mg/mL) to TNBS solution, the
6 peptide concentration per mg of GO nano-sheets was calculated for each sample (Schematic 2).

7 2.3.3. Cell culture and cytotoxicity assay

8 L929 fibroblast cells were cultured in Dulbecco's modified eagle medium (DMEM)
9 containing 10% fetal bovine serum (FBS), streptomycin (100 $\mu\text{g}/\text{mL}$), penicillin (100 $\mu\text{g}/\text{mL}$),
10 at 37 $^{\circ}\text{C}$ in a humidified 5% CO_2 -containing atmosphere. The cytotoxicity of different samples in
11 comparison with NGOS, R8 and PEI as controls was evaluated using MTT assay. Briefly, the
12 fibroblast cells were seeded in a 96-well plate at a density of 10^4 cells/well. After 24 h
13 incubation, the culture media were replaced with 100 μL of fresh media containing the samples.
14 After an additional 24 h, the cells were washed with PBS and 20 μL of MTT (5 mg/mL) solution
15 in phosphate buffered saline (PBS) was added to each well and incubated for another 4 h. The
16 supernatant was then removed and the formazan crystals were dissolved in DMSO (100 μL per
17 well). The absorbance was read at 570 nm by a micro-plate reader (Model 680 Bio-RAD) and
18 reported as the percentage of cell viability compared to the controls.

19 2.3.4. In vitro gene transfection assay

20 A DNA plasmid encoding enhanced green fluorescence protein (EGFP) is used as a gene
21 model to study the transfection ability of peptide-functionalized samples. The reporter plasmid
22 pEGFP was transformed in E. Coli DH5a and was amplified in Luria-Bertani (LB) medium at
23 37 $^{\circ}\text{C}$ overnight at 250 rpm. The plasmids were purified by a high pure plasmid isolation kit
24 (Roche, Germany) according to the manufacturer's protocol. The concentration and purity of
25 plasmids were determined by UV absorbance measurements at 260 and 280 nm. The plasmids
26 were preserved at -20 $^{\circ}\text{C}$ prior to use.

27 Before *in vitro* gene transfection experiment, the pDNA loading and complexion capability of
28 synthesized nano-carriers was investigated by gel retardation assay. Complexes of pDNA with
29 NGOS, GOPs, and different concentration of pure peptides were prepared by the addition of
30 sample suspensions (10 μL) to the pDNA solution (10 μL) followed by 30 min incubation at
31 room temperature. The complexes were then electrophoresed through a 1% (w/v) agarose gel
32 containing ethidium bromide (EtBr, 0.5 $\mu\text{g}/\text{mL}$) in 0.5 TAE (Tris -acetate-EDTA) buffer at 100
33 V for 30 min. The gel was subsequently analyzed on a UV illuminator (wise UV WUV,
34 DAIHAN Scientific, Seoul, Korea).

35 *In vitro* transfection experiment of R8-NGOSs was qualitatively assessed against HEK 293
36 (Human Embryonic Kidney 293) cells by fluorescence microscopy. The cells were cultured in a
37 24-well culture plate at an initial density of 3×10^4 cells/ml and incubated for 24 h. Under a mild
38 pipetting condition, 10 μL of each sample (100 $\mu\text{g}/\text{mL}$) which was diluted in 100 μL of serum
39 free media was mixed with 1 μg of pDNA (10 μL) and incubated for 30 min at room temperature
40 for complexion. The cells were then incubated with each complex in 250 μL serum free media
41 for 5 h, followed by 18 h incubation in 750 μL of FBS containing media. Pure R8 peptide and
42 PEI (10 4 g/mol) with the concentration of 100 $\mu\text{g}/\text{mL}$ were used as controls. The transfection of
43 the cells was analyzed by a fluorescence microscope (TCS SP5 Leica).

Besides fluorescent imaging, to quantitatively evaluate gene transfection ability of optimized nano-carrier and to study the effect of serum on transfection efficacy, intensity of GFP expression was measured after 48 h transfection by a Microplate Reader (SpectraMax i3 Multi-Mode, Molecular devices). Briefly, 250ng of pEGFP was mixed to 10 μ L of GOP1 (50 μ g/mL) according to the same procedure as above. HEK 293 cells were seeded in 96-well plates (100 μ L media+10% FBS), 24 h prior to transfection assay. The media was removed then and the cells were washed with PBS. Subsequently, 100 μ L DMEM (in presence and absence of serum protein, FBS) contained complexes was gently added to the cells. After 8 h of incubation, the transfection medium was removed, and 200 μ L fresh media (DMEM containing 10% FBS) was added for another 40h incubation. Finally, cells were washed with PBS (3 times) and the fluorescent intensity of GFP was read by a micro-plate reader (excitation: 480nm, emission: 520 nm). As for controls, the cells without any treatments, cells treated by JetPEI® (Poluplus transfection Inc, New York) and cells treated by naked pEGFP (250 ng) were used as blank sample, positive control and negative control, respectively. The relative transfection ability of the samples was expressed as relative fluorescence intensity calculated based on equation (1):

$$\text{Relative Fluorescence Intensity} = (E_t - E_b) / E_{c+} \quad \text{Eq. 1}$$

Where E_t , E_b and E_{c+} represent average fluorescence emission of test samples, blank sample and positive control (JetPEI®, +FBS), respectively.

2.4. Statistical analysis

Statistical analysis was carried out using SPSS software (v 17.0; IBM New York, NY, USA). Data were first analyzed by analysis of variance (ANOVA); when statistical differences were detected, a Tukey's Multiple Comparison test was performed. Data are reported as mean \pm SD at a significance level of $p < 0.05$.

3. Results and discussion

3.1. FTIR spectroscopy

The chemical structure of synthesized NGOS, NGOS-COOH and R8-functionalized NGOS samples were characterized by FTIR spectroscopy (Fig.1). The FTIR analysis demonstrated the successful synthesis of NGOS. The appearance of characteristic absorption peaks at 3410, 1733, 1620 and 1520 cm^{-1} revealed the presence of OH, C=O, COOH and C=C functional groups in NGOS, respectively. After chloroacetic acid activation, the resulting NGOS-COOH derivative showed a stronger absorption band at 1620 cm^{-1} which is an indication for the formation of more carboxylate moieties. The peak at \sim 1230 cm^{-1} is attributed to the vibration mode of epoxide groups (C-O-C) which is more pronounced in the NGOS spectra compared to carboxylated samples where the peak is almost vanished. This is possibly due to the synergistic effects of chloroacetic acid on both epoxide and hydroxyl groups. After NGOS reaction with chloroacetic acid, two strong peaks at 2854 and 2925 cm^{-1} were appeared which are correlated to the symmetric and asymmetric stretching modes of -CH₂- groups in chloroacetic acid. The peak at 1390-1400 is also attributed to the deformation vibration of -CH₂- group²⁷. The small peak at \sim 2360 cm^{-1} is associated to the O-H stretch from strongly hydrogen-bonded -COOH which could confirm the chemical attachment of many -O-CH₂-COOH to the NGOS sheets²⁸.

After conjugation of R8 peptide to the NGOS-COOH, a characteristic band at 1742 cm^{-1} (stretching vibration of CONH) was appeared which indicated the successful formation of R8-NGOS. This was also confirmed by the appearance of two main characteristic peaks of

1 octaarginine at 1463 cm^{-1} (amide II) and 1651 cm^{-1} . The prominent peak at 1667 cm^{-1} is assigned
2 to guanidine C=N stretching and C=O carbonyl stretch of octaarginine whereas the peak at 1139
3 cm^{-1} is attributed to C–N stretching. The N-H stretching of primary and secondary amine groups
4 of guanidine were presented near 3100-3500. The comparison between the FTIR spectra before
5 and after R8 conjugation to the NGOS confirmed the successful binding of octaarginine to the
6 nano-carriers as the amide group peaks of R8-NGOS were appeared (Fig. 1).

7 3.2. *Uv-vis spectroscopy*

8 The peptide functionalized NGOS was further characterized by Uv-vis spectroscopy. As
9 shown in Fig. 3a, the NGOS showed a characteristic peak at 231 nm corresponds to $\pi\text{-}\pi^*$
10 transitions of C=C bonds as well as a shoulder at 300 nm corresponds to $\sigma\text{-}\pi^*$ transitions of
11 carboxyl bonds. The carboxylated sample showed a much higher absorbance in the Vis-NIR
12 range as compared to the NGOS. The significant increase in the absorbance was led to a
13 darkening of the solution which can clearly be seen with the eye (Fig. 3a, inset) [4, 6]. The Uv-
14 vis spectrum of R8 solution (0.01 mg/mL) showed a characteristic peak at $\sim 208\text{ nm}$ which is
15 correlated to guanidine group of R8 (Fig. 3b). The R8-NGOS showed both dominant peaks of
16 graphene oxide and R8 around 240 and 200 nm, respectively. The shift of these peaks is
17 attributed to the amidation and reduction of NGOS after the R8 peptide conjugation^{30, 31}.

18 3.3. *XRD analysis*

19 The distances between the sheets as well as their folding and structural disruptions in graphite
20 and its functionalized derivatives are highly different²⁷. Therefore, the graphite, NGOS,
21 carboxylated and peptide functionalized samples were characterized by XRD for more structural
22 analysis. The XRD patterns confirmed the chemical oxidation of the exfoliated graphite and
23 formation of GO sheets (Fig. 3c). The typical diffraction peak of native graphite was observed at
24 $2\theta = 26.8$. The oxidation process was resulted in the formation of hydroxyl and epoxy groups as
25 well as carboxyl groups mainly located on the center and lateral sides of the sheets, respectively.
26 The inclusion of these functional groups resulted in a weakening of *van der Waals* force between
27 the graphene sheets in the exfoliated GO. The appearance of diffraction peak of NGOS at $2\theta =$
28 12.3 with no reflection at $2\theta = 26.8$ indicated that the exfoliation process under strong acidic
29 condition had increased the sheets spacing [7]. Further carboxylation process under basic
30 condition was resulted in a more dispersion and exfoliation of nano-sheets probably duo to the
31 addition of chloroacetic acid residue ($-\text{O}-\text{CH}_2-\text{COOH}$). As the result, the carboxylated sample
32 showed much weaker and broader diffraction peak at $2\theta = 12.3$ as compared to the NGOS which
33 indicates an increase in the interlayer spacing. For R8-functionalized sample, the weakest
34 diffraction peak was detected at $2\theta = 12.6$ which is corresponded to a slightly higher d-spacing
35 rather than that of the NGOS-COOH. It is evident that the increase in the interlayer spacing
36 between GO sheets is because of functionalization of graphene sheets by R8 molecules.

37 3.4. *Size and morphology analyses*

38 The size and morphology of NGOS, NGOS-COOH and R8-conjugated samples having
39 various conjugation degrees were investigated by AFM and TEM. The AFM images of as
40 prepared NGOS indicated a sheet-like morphology with the size of 250-400 nm. The AFM was
41 used more for lateral size and thickness measurement of nano-sheets. Based on our AFM data,
42 the nano-sheets appeared to be highly varied in shapes and lateral sizes. However, the z-section
43 analysis for thickness measurement of nano-sheets after chloroacetic acid treatment and R8
44 conjugation showed a consistent results and confirmed sheets exfoliation and peptide

1 conjugation, respectively. The thickness of unmodified NGOS which measured from the height
2 profile of the AFM image was about 1-1.5 nm. This thickness is corresponded to 1-2 layered
3 graphene sheets (Fig. 2a). Modification of NGOS using chloroacetic acid followed by peptide
4 conjugation changed nano-sheet thickness (Fig. 2b,2c). The carboxylated sample mean thickness
5 was about 0.8 nm indicating the formation of a single layered sheet (Fig. 2b). The TEM analysis
6 provided more detailed morphological insight on the samples (Fig. 2d). Based on the TEM
7 images, typical wrinkle morphology for the GO and its exfoliation into a single or very thin layer
8 after carboxylation treatment was observed. The smaller size of the carboxyl functionalized
9 sample could be caused by the sonication process which was involved in the activation step. Duo
10 to the strong basic condition of carboxylation process, the modified samples showed reduced size
11 of 100-200 nm²⁹. The size reduction of carboxylated GO could be more attractive for biological
12 interactions particularly gene and drug deliveries where a larger surface area is necessary for
13 biomolecular conjugation.

14 The DLS measurement was also used for an estimation and comparison of size alteration
15 among the samples as the concentration of the peptide increased (Table 1). Before running DLS,
16 to remove large non-uniformed nano-sheets observed by AFM, the NGOS and NGOS-COOH as-
17 prepared solutions centrifuged for 5 min (14000 rpm). This could be the reason that DLS showed
18 smaller average size for NGOS and NGOS-COOH compared to AFM analysis. However, the
19 DLS characterization could not reveal the accurate size of nano-sheets in aqueous solution, as it
20 considers the GO sheets spherical in shape whereas they are more accurately 2-D objects.
21 Therefore, the average nano-sheets diameter reported from DLS is rather the effective
22 hydrodynamic diameter of an equivalent sphere described by the tumbling of the nano-sheets.
23 Additionally, even though GO nano-sheets seems rigid when deposited on an atomically flat
24 surface (for the AFM experiment), in reality they are highly pliant sheets that could easily
25 conform to any figure on that surface.

26 The height topographical study of R8-NGOS by AFM indicated that the peptide chains were
27 successfully grafted onto the surface of GO sheets. Interestingly, the peptide grafted samples
28 showed a reduced size of 50-100 nm and increased thickness of 3-7 nm. After the covalent
29 modification of GO with R8, many protuberances were observed on the surface of nano-sheets
30 that suggests immobilization of a large amount of peptides onto the basal plane of GO sheets.
31 The most of R8-conjugated nano-sheets showed domed morphology while GO sheets showed
32 very sharp edges with flat surface. In contrast, on non-carboxylated samples (NGOS), most of
33 the peptide chains seem to graft on the basal parts of the sheets rather than the edges (Fig. 2c).

34 The increase in the peptide to GO ratios from 0.1 to 1.5 showed to gradually increase the
35 thickness of the samples from 3 to 10 nm. For GOP1 sample, the AFM image indicated a
36 successful peptide conjugation on the single sheet.

37 3.5. TNBS assay

38 In non-viral based gene delivery, one of the least studied areas which may directly affect
39 cellular uptake efficacy is the influence of peptide density on nano-carriers. Khalil et al. have
40 shown that the density of R8 peptide on liposomal nano-carrier would affect the uptake
41 mechanism which directly influence the intracellular trafficking and results in different levels of
42 gene expression³⁵. In order to quantify the R8 peptides molarity on the R8-functionalized NGOS
43 samples, TNBS assay was used. The TNBS would react with primary amino groups of amino
44 acids in aqueous solution (pH=8) and form a yellow component which can be detected at 345 nm

1 (Schematic 2). It should be noted that the guanidine amine groups react with TNBS at slower
2 rate than primary N-terminal amine groups.

3 To quantify the peptide functionalization efficacy, the absorbance value of the samples after
4 interaction with TNBS solution was read and compared using a plotted standard curve (Fig. 5).
5 The measurement was performed comparatively to optimize the reaction condition among the
6 samples. However, ideally, it would be more relevant to use N-terminally acetylated analog of
7 the R8 peptide to prepare calibration curve. The results confirmed the binding of the peptide
8 chains on the GO nano-sheets. The amount of bonded R8 peptides ($\mu\text{mol}/\text{mg}$) and conjugation
9 efficacy were calculated and listed in Tables 2. It can be seen that the amount of bounded peptide
10 is proportional to the initial concentration of peptide being used. As the initial amount of peptide
11 increased, the GOP1 showed the highest conjugation efficacy among the samples. However, the
12 conjugation efficacy decreased in GOP1.5 rather than GOP1. It is therefore essential to optimize
13 the conjugation process in term of the amount of bonded peptide molarity per mg of GO nano-
14 sheets.

15 *3.6. Zeta potential and dispersion stability analyses*

16 Zeta potential is an important factor for characterization of dispersion stability of colloidal
17 systems. It is directly influenced by the electrostatic interaction between different functionalized
18 graphene sheets and other biomolecules [30]. The surface charges of the NGOS before and after
19 carboxylation process with chloroacetic acid were determined (Table. 1). As depicted in table 1,
20 the activation of graphene oxide sheets by chloroacetic acid under basic condition decreased zeta
21 potential of NGOS due to the introduction of more carboxylic groups. This is advantageous as it
22 provides a better condition for subsequent peptide conjugation. Furthermore, due to the
23 hydrophilic nature of the carboxylated graphene nano-sheets, the dried powder can readily be
24 exfoliated in water and form a stable colloidal suspension under a mild sonication treatment. The
25 carboxylated sample was highly dispersed even after 3 months without any precipitation whilst
26 unmodified NGOS underwent colloidal instability after this period of time. There was no
27 significant change in NGOS-COOH size even after 3 month incubation (93 ± 4.3 compared to
28 85 ± 2.5), whereas for the untreated GO, a significant increase in size was detected by DLS
29 measurement (478 ± 33 compared to 110 ± 6).

30 The zeta potential measurement was also carried out on the peptide functionalized GO
31 samples having different amounts of the R8 peptide. The results showed that by conjugation of
32 R8 on the graphene nano-sheets zeta potential was significantly increased which is a
33 confirmation on the addition of positively charged amine groups of R8. It was revealed that the
34 R8:GO ratios of 0.5:1, 1:1 and 1.5:1 resulted in a significant increase in zeta potential as
35 compared to the NGOS-COOH.

36 An increase in size was detected when the amount of R8 peptide increased from 0.5 to 1
37 $\mu\text{mol}/\text{mg}$. The size increase was significant when the amount of R8 peptide was enhanced from 1
38 to 1.5 $\mu\text{mol}/\text{mg}$. However, a significant increase in size distribution was detected for GOP1.5.
39 This result is confirmed by the instability test observed for GOP1.5 which presented a partial
40 aggregation during incubation at room temperature (Fig. 4). The stability of the peptide-
41 functionalized NGOS was also analyzed by DLS measurements (Table 3). It is demonstrated that
42 for GOP0.1, GOP0.5 and GOP1 there was no significant size alterations during incubation in
43 deionized water or culture media (DMEM+10% FBS) after 48 h which indicates a good colloidal
44 stability of prepared nano-carriers. However, all the samples showed slight size increase after 1h

1 incubation in culture media compared to deionized water which could be due to surface
2 absorption of serum proteins³². A significant instability was observed for the GOP1.5 sample
3 even after 6 h incubation in culture media (Fig.4). After 48h, the aggregates were large enough to
4 sediment and their size was around 1 μm and 800 nm in DMEM and DI water, respectively
5 (Table 3).

6 The results of TNBS assay and zeta potential analysis revealed that as the concentration of the
7 peptide increased (from GOP0.1 to GOP 1.5) the amount of conjugated peptide and the positive
8 charges increased. However, gel electrophoresis data showed less DNA condensation in GOP1.5
9 compared to GOP1. We speculated that the extra peptide chains could bridge between two or
10 more nano-sheets and cause inter-particle crosslinking as the concentration of peptide increased.
11 Although there is no chemical evidence to confirm whether the peptide-mediated cross-linking is
12 due to covalent binding or physical interactions, based on the DLS results it is apparent that the
13 inter-particle crosslinking of GOP1.5 nanoparticles is mostly covalent. Size and polydispersity
14 index (PDI) analyses immediately after a harsh sonication process showed a significant increase
15 as the concentration of peptide enhanced from GOP1 to GOP1.5 suggesting a larger particle size
16 distribution. The non-uniformed size distribution for GOP1.5 suggests formation of some nano-
17 clusters (resulted from peptide mediated covalent cross linking). Although the guanidine amine
18 groups are less reactive than N-terminal amines, their high density and availability in the peptide
19 chains could increase their possible reactivity during the reaction.

20 The inter-particle crosslinking could restrict the interaction of peptide chains with pDNA which
21 resulted in less condensation observed in the electrophoresis assay. This is also in agreement
22 with the previous study on TAT-immobilized gold nanoparticles (AuNPs) which reported the
23 instability and aggregation of AuNPs with increasing TAT concentration up to 2 $\mu\text{g}/\text{mL}$ ³³.
24 Sterling et. al. has studies surface modification of Au nanoparticles by covalent conjugation of
25 $\text{NH}_2\text{-PEG- NH}_2$ using EDC/NHS. They have reported the inter-particle crosslinking by
26 increasing $\text{NH}_2\text{-PEG- NH}_2$ ratio to Au nanoparticle³⁴. It can be assumed that the concentration
27 of peptide can then strongly affect chains conjugation of GO nano-sheets and result in reduced
28 conjugational efficacy due to the partial intra-particle crosslinking.

29 The size of nano-carriers/plasmid complexes was evaluated using DLS after 30 min
30 incubation of 1 μg pEGFP with 10 μg of GOP samples suspended in deionized water (Table 1).
31 The increase in size of GOP0.5 and GOP1 upon complexation with pEGFP could be explained
32 by electrostatic interaction between the negatively charged plasmid and positively charged
33 GOP0.5 and GOP1 nano-carrier formulations. This could be justified to successful complexation
34 and plasmid loading on these samples. As it was expected based on the zeta value for GOP0.1,
35 there is no significant size increase after incubation with plasmid. In the case of GOP1.5/pDNA,
36 the size distribution was variable and it is assumed that further incubation in presence of plasmid
37 may trigger precipitation of the complexes.

38 3.7. Cytotoxicity assay

39 The viability of fibroblast cells (L929) treated by NGOS, R8, and GOPs in the absence of
40 plasmid after 48 h incubation was determined by MTT assay. The results showed that cell
41 viability remained above 85% even after the addition of 250 $\mu\text{g}/\text{mL}$ NGOS. There was a
42 reduction in cell viability after the addition of 10, 50, and 100 $\mu\text{g}/\text{mL}$ of NGOS by 7.5, 11 and
43 10%, respectively, compared to the non-treated cells. However, the reduction in viability of cells
44 was not statistically significant (Fig.6). It is known that the addition of CPPs at certain
45 concentrations could enhance gene expression. However, these concentrations were mostly

1 increased the risk of cytotoxicity and immunogenicity³⁶. To explore the optimum concentration
2 of R8 peptide for conjugation to GO nano-sheets, four different concentrations of peptide were
3 used. The MTT results showed the highest cell viability with the addition of 50 µg/mL R8
4 peptide. The addition of 100 µg/mL R8 peptide reduced the relative cell viability slightly
5 compared to the other samples and significantly compared to the control. The conjugation of R8
6 to NGOS showed no cell toxicity even after the addition of 250 µg/ml of nano-carriers. By
7 varying conjugation ratio of peptide to NGOS, no significant cytotoxicity was detected after
8 incubation of L929 cells with GOPs at the concentration of 100 µg/mL. All the samples with
9 various conjugation ratios of peptide presented comparable cell viabilities to the non-treated
10 sample used as control. However, PEI treated cells at the same concentration with GOPs (100
11 µg/ml) showed significant decrease in cell viability compared to the control. In addition, light
12 microscopy images revealed similar morphology for the cells treated with R8-NGOS and un-
13 treated ones. (Fig.7). These results suggested that the peptide modified NGOS was not cytotoxic
14 in any of concentrations being used and had no apparent effect on proliferation inhibition of the
15 cells.

16 *3.8. Gene transfection*

17 *3.8.1. Gel retardation assay*

18 For successful gene delivery a gene carrier that interacts with genetically materials such as
19 pDNA generally through electrostatic interaction is essential. The NGOS possess surface
20 negative charges and inherently does not interact with pDNA with a negatively charged
21 phosphate backbone. It is crucial to modify the NGOS with cationic peptides like R8 in order to
22 acquire more positive surface charge and enable the formation of nano-complex with pDNA. The
23 formation of nano-complexes which consist of nano-carriers and pDNA was examined by
24 agarose gel electrophoresis. As depicted in Fig 8a, the peptide functionalized NGOS strongly
25 condensed pDNA more clearly for GOP0.5 and GOP1. In the GOP1.5 it seems that the bonded
26 peptide chains were not enabled to interact with pDNA and retard migration. It was also revealed
27 that the migration of pDNA completely was retarded when the R8 concentration was more than 1
28 µg/mL (Fig. 8b) whereas none of the NGOS concentrations could retard pDNA migration under
29 applied electrical field (Fig. 8c). According to zeta potential results, GOP1 and GOP1.5 showed
30 the most positively charged surfaces among the peptide functionalized samples, therefore, it is
31 expected that they could efficiently form complexes with pDNA and retard migration. However,
32 the negatively charged GOP0.1 and GOP0.5 also showed plasmid retardation ability. Similar
33 observations was previously reported by Sanz et al. regarding siRNA loading on gold nano-
34 particles modified with TAT cell penetration peptide. This phenomenon cannot be purely
35 explained by the electrostatic interactions between positive charges of peptide and negative
36 charges of phosphate in DNA. It is assumed that some hydrogen bonding may be formed
37 between amide groups (peptide bond) and hydroxyl group in ribose groups of DNA. This could
38 be the reason that the weak negatively charged GOP nano-sheets showed a strong pDNA
39 complexion and retardation. Although GOP1.5 showed higher conjugated peptide per mg of
40 NGOS, GOP1 showed the most condensed pDNA. This could be another confirmation for the
41 fact that peptide chains in GOP1.5 are not free enough to interact with plasmids duo to inter-
42 particle crosslinking.

43 *3.8.2. Transfection assay*

1 The ability of the GOPs as gene vector to transfer pEGFP into the HEK cells was evaluated
2 by fluorescence microscopy. The PEI 10⁴Da/pDNA and R8/pDNA binary complexes with
3 similar concentrations were used as controls. The fluorescent intensity of the transfected cells
4 was correlated to the transfection efficiency. It was found that naked pEGFP and NGOS-pDNA
5 failed to result EGFP expression in the HEK cells. Among peptide conjugated samples, GOP1
6 showed the most efficient delivery of the pEGFP into the treated cells and highest gene
7 expression after 48 h incubation (Fig. 9). The cells treated with the GOP1 sample exhibited much
8 stronger fluorescence intensity than those transfected with naked R8 while the GOP1.5 showed
9 slight aggregation during incubation. Although the PEI transfected cells expressed EGFP, most
10 of the cells were found nonviable due to its cytotoxicity. It was concluded that the maximum
11 transfection efficiency could be achieved using peptide to GO ratio of 1 μmol:1mg (GOP1).

12 Quantitative assessment of transfection ability of samples based on fluorescent intensity of
13 expressed GFP in presence and absence of serum protein was performed and compared with
14 JetPEI® as a commercial transfection reagent. Based on the manufacture's protocol, JetPEI®
15 was used in the presence of serum. The results showed GOP0.5 and GOP1 provide higher
16 transfection ability (51% and 72%, respectively) rather than two other GOP formulations (Fig.
17 9). This is consistent with pDNA condensation assay observed with gel electrophoresis. The
18 transfection efficacy showed a slight decline in presence of FBS, however; this decrease was not
19 significant for any of GOP0.5 and GOP1. In the presence of FBS the transfection ability of
20 GOP1.5 decreased 7 times which is evidenced by the instability observed during incubation with
21 cell culture media (Fig. 9d). Even though the transfection ability of GOP1 was lower than that of
22 Jet PEI®, it was the most efficient sample and considered the optimized R8-functionalized
23 NGOS sample for gene delivery applications.

24 4. Summary and conclusion

25 Cell-penetrating peptides (CPPs) have gained much attention in recent years due to their
26 ability to translocate drugs, genes, and large therapeutic molecules. One commonly used CPP
27 group is polyarginine. The efficient cell-penetrating characteristic of polyarginine is related to
28 rich domain residues of arginine that interacts with negatively charged proteoglycans on the cell
29 membrane. In this study R8 was utilized to modify the graphene oxide surface to be used as an
30 efficient gene delivery carrier. The influences of R8 conjugation ratio on the synthesized nano-
31 graphene oxide particle size and surface charge as well as peptide conjugation density as
32 important factors in cellular uptake were investigated. The R8-NGOS sample with peptide molar
33 ratio of 1 μmol per mg of GO showed to be the most efficient and biocompatible gene delivery
34 vehicle having desirable properties such as strong positive charge and good stability in aqueous
35 solutions. It was also suggested that increasing peptide molar ratio from 1 to 1.5 μmol/mg may
36 trigger inter-particle crosslinking via peptide chains which resulted in partial instability and
37 nano-particles agglomeration. The optimized R8-NGOS sample showed efficient plasmid
38 condensation, EGFP expression and high cell viability compared to PEI which is recognized as
39 the 'golden standard' cationic polymer for gene transfection. The promising results altogether
40 imply the potential of optimized R8-functionalized system as efficient non-viral gene delivery
41 nano-carrier for gene therapy applications. However, the future studies should be directed toward
42 increasing the stability of peptide functionalized NGOS in higher peptide conjugation ratios
43 while avoiding inter-particle peptide crosslinking.

44 Acknowledgments

1 The authors wish to thank financial supports provided for this work by National Institute of
2 Genetic Engineering and Biotechnology (NIGEB). We also gratefully acknowledge the scientific
3 help and guidance of Hojatollah Vali, Mahdi Amrollahi and Mohammad Hasan
4 Mohammadzadeh.

1 **References:**

- 2 1. T. Niidome and L. Huang, *Gene therapy*, 2002, 9, 1647-1652.
- 3 2. L. De Laporte, J. Cruz Rea and L. D. Shea, *Biomaterials*, 2006, 27, 947-954.
- 4 3. A. Lam and D. Dean, *Gene therapy*, 2010, 17, 439-447.
- 5 4. N. Sanvicens and M. P. Marco, *Trends in biotechnology*, 2008, 26, 425-433.
- 6 5. Z. Liu, S. Tabakman, K. Welsher and H. Dai, *Nano research*, 2009, 2, 85-120.
- 7 6. S.-r. Ji, C. Liu, B. Zhang, F. Yang, J. Xu, J. Long, C. Jin, D.-l. Fu, Q.-x. Ni and X.-j. Yu, *Biochimica et*
8 *Biophysica Acta (BBA) - Reviews on Cancer*, 2010, 1806, 29-35.
- 9 7. V. Singh, D. Joung, L. Zhai, S. Das, S. I. Khondaker and S. Seal, *Progress in Materials Science*,
10 2011, 56, 1178-1271.
- 11 8. Y. Zhu, S. Murali, W. Cai, X. Li, J. W. Suk, J. R. Potts and R. S. Ruoff, *Advanced Materials*, 2010, 22,
12 3906-3924.
- 13 9. V. C. Sanchez, A. Jachak, R. H. Hurt and A. B. Kane, *Chem Res Toxicol*, 2012, 25, 15-34.
- 14 10. X. Sun, Z. Liu, K. Welsher, J. T. Robinson, A. Goodwin, S. Zaric and H. Dai, *Nano research*, 2008, 1,
15 203-212.
- 16 11. Y. Wang, Z. Li, J. Wang, J. Li and Y. Lin, *Trends Biotechnol*, 2011, 29, 205-212.
- 17 12. Z. Liu, J. T. Robinson, X. Sun and H. Dai, *Journal of the American Chemical Society*, 2008, 130,
18 10876-10877.
- 19 13. B. Chen, M. Liu, L. Zhang, J. Huang, J. Yao and Z. Zhang, *Journal of Materials Chemistry*, 2011, 21,
20 7736-7741.
- 21 14. L. Feng, S. Zhang and Z. Liu, *Nanoscale*, 2011, 3, 1252-1257.
- 22 15. H. Dong, L. Ding, F. Yan, H. Ji and H. Ju, *Biomaterials*, 2011, 32, 3875-3882.
- 23 16. L. Feng, S. Zhang and Z. Liu, *Nanoscale*, 2011, 3, 1252-1257.
- 24 17. H. Kim, R. Namgung, K. Singha, I.-K. Oh and W. J. Kim, *Bioconjugate chemistry*, 2011, 22, 2558-
25 2567.
- 26 18. H. Bao, Y. Pan, Y. Ping, N. G. Sahoo, T. Wu, L. Li, J. Li and L. H. Gan, *Small*, 2011, 7, 1569-1578.
- 27 19. X. Yang, G. Niu, X. Cao, Y. Wen, R. Xiang, H. Duan and Y. Chen, *Journal of Materials Chemistry*,
28 2012, 22, 6649-6654.
- 29 20. M. Mae and U. Langel, *Curr Opin Pharmacol*, 2006, 6, 509-514.
- 30 21. R. M. Johnson, S. D. Harrison and D. Maclean, in *Cell-Penetrating Peptides*, Springer, 2011, pp.
31 535-551.
- 32 22. F. Shiroh, *International Journal of Pharmaceutics*, 2002, 245, 1-7.
- 33 23. D. M. Copolovici, K. Langel, E. Eriste and U. I. Langel, *ACS nano*, 2014, 8, 1972-1994.
- 34 24. H. Yukawa, Y. Kagami, M. Watanabe, K. Oishi, Y. Miyamoto, Y. Okamoto, M. Tokeshi, N. Kaji, H.
35 Noguchi and K. Ono, *Biomaterials*, 2010, 31, 4094-4103.
- 36 25. W. Hummers and R. Offeman, *J Am Chem Soc*, 1958, 80, 1339-1345.
- 37 26. J. Shen, M. Shi, B. Yan, H. Ma, N. Li, Y. Hu and M. Ye, *Colloids and Surfaces B: Biointerfaces*, 2010,
38 81, 434-438.
- 39 27. L. Zhang, J. Liang, Y. Huang, Y. Ma, Y. Wang and Y. Chen, *Carbon*, 2009, 47, 3365-3368.
- 40 28. W. Davis, C. Erickson, C. Johnston, J. Delfino and J. Porter, *Chemosphere*, 1999, 38, 2913-2928.
- 41 29. T. Szabó, E. Tombácz, E. Illés and I. Dékány, *Carbon*, 2006, 44, 537-545.
- 42 30. H. Kim and W. J. Kim, *Small*, 2014, 10, 117-126.
- 43 31. Q. Yang, X. Pan, K. Clarke and K. Li, *Industrial & Engineering Chemistry Research*, 2011, 51, 310-
44 317.
- 45 32. R. Foldbjerg, E. S. Irving, J. Wang, K. Thorsen, D. S. Sutherland, H. Autrup and C. Beer, *Toxicology*
46 *Research*, 2014.
- 47 33. V. Sanz, J. Conde, Y. Hernández, P. V. Baptista, M. Ibarra and M. Jesús, *Journal of Nanoparticle*
48 *Research*, 2012, 14, 1-9.

- 1 34. R. A. Sperling, T. Pellegrino, J. K. Li, W. H. Chang and W. J. Parak, *Advanced Functional Materials*,
2 2006, 16, 943-948.
- 3 35. I. A. Khalil, K. Kogure, S. Futaki and H. Harashima, *Journal of Biological Chemistry*, 2006, 281,
4 3544-3551.
- 5 36. K. Saar, M. Lindgren, M. Hansen, E. Eiríksdóttir, Y. Jiang, K. Rosenthal-Aizman, M. Sassian and Ü.
6 Langel, *Analytical biochemistry*, 2005, 345, 55-65.

7

8

9

1

Figure Captions

2 **Table 1.** Zeta potential and DLS particle size analyses. For zeta potential value and particle size
3 (-pDNA), * p -value<0.005 compared to NGOS-COOH and ** p -value<0.001 compared to the
4 other samples and control. For particle size analysis (+pDNA), * p -value<0.005 and ** p -
5 value<0.001 compared to the particle size before pDNA condensation and ** p -
6 value<0.001 compared to other samples.

7 **Table 2.** The quantification of conjugated peptide and reaction efficacy on the NGOS based on
8 TNBS assay. * p -value<0.005 compared to the other samples.

9 **Table 3.** DLS particle size analysis after incubation in cell culture medium and DI water for 1
10 and 48 h. * p -value<0.005 compared to the particle size after 1 h incubation.

11 **Schematic 1.** A representation of structure and main functional groups of (a) GO (b)
12 octaarginine (R8).

13 **Schematic 2.** A representation of TNBS assay for quantification of amine groups' molarity per
14 mg of R8-NGOS.

15 **Figure 1.** FTIR spectra of NGOS, NGOS-COOH and R8- functionalized NGOS.

16 **Figure 2.** Size and morphological characterization of synthesized NGOS, NGOS-COOH and
17 R8-NGOS: AFM image of (a) NGOS (b) carboxylated GO and (c) R8-NGOS (GOP1). The TEM
18 image of (d) as-prepared NGOS (up) chloroacetic acid treated NGOS (down). The arrows show a
19 NGOS-COOH single nano-sheet.

20 **Figure 3.** Uv-vis spectra of (a) NGOS and carboxylated NGOS in aqueous solution (b) R8 and
21 R8-NGOS (all samples concentration was 0.01 mg/mL). (c) The XRD patterns of NGOS,
22 NGOS-COOH and R8-NGOS.

23 **Figure 4.** The dispersibility and colloidal stability of peptide-functionalized samples: (a) after
24 48h incubation at room temperature (b) after 6h incubation with cell culture media supplemented
25 with FBS at 37°C.

26 **Figure 5.** Absorption peaks of TNBS solution after reaction with different concentrations of R8.
27 The inset shows the calibration curve that presents the relation between absorbance and
28 concentration at 345nm.

29 **Figure 6.** Histogram represents cell viability based on MTT assay for NGOS and R8 at different
30 concentrations as well as R8-functionalized NGOS with various peptide conjugation ratios
31 (100µg/mL). All samples compared to control (non-treated cells) * p <0.05 and ** p <0.005.

32 **Figure 7.** Optical microscopic images of L929 cells morphology of none treated cells (a) after
33 24h and (b) 48 h in comparison with cells incubated with GOP1 (c) after 24 h (d) 48 h.

34 **Figure 8.** Agarose gel retardation assay of pEGFP complexed with (a) R8-conjugated samples,
35 (b) R8 and (c) NGOS.

36 **Figure 9.** The HEK293 cell line treated with GOP1-pEGFP complex after 48 h (a) transmission
37 image (b) fluorescent image and (c) merged images. Quantification of transfection ability after
38 48 h of cell transfection in presence and absence of FBS (d). * p -value<0.005 compared to
39 transfection ability in the absence of FBS.

1 **Table 1.** Zeta potential and DLS particle size analyses. For zeta potential value and particle size
 2 (-pDNA), * p -value<0.005 compared to NGOS-COOH and ** p -value<0.001 compared to the
 3 other samples and control. For particle size analysis (+pDNA), * p -value<0.005 and ** p -
 4 value<0.001 compared to the particle size before pDNA condensation and ** p -
 5 value<0.001 compared to other samples.

Sample	Zeta potential value(mv)	Particle size analysis (- pDNA)		Particle size analysis (+ pDNA)	
		Effective	PDI	Effective	PDI
		diameter (nm)		diameter (nm)	
NGOS	-35±1.5	110±6	0.002±0.001	-	-
NGOS-COOH	-46±0.8	85±2.5	0.005±0.001	-	-
GOP0.1	-33±1.7	95±3.1	0.011±0.007	101±5.1	0.1±0.014
GOP0.5	-7±0.1*	123±13*	0.100±0.014	195±7.2*	0.23±0.009
GOP1	+23±0.4*	168±18*	0.050±0.008	277±6.4*	0.29±0.031
GOP1.5	+31±2.2*	322±20*	0.37±0.065**	550± 87*	0.45±0.08**

PDI: Polydispersity index

6

7

1 **Table 2.** The quantification of conjugated peptide and reaction efficacy on the NGOS based on
 2 TNBS assay. * p -value<0.005 compared to the other samples.

Sample	Conjugated-R8 ($\mu\text{mol}/\text{mg}$)	Estimated Number of R8 molecules per 1 mg of NGOS (\times 10^{-15})	Conjugation Efficacy%
GOP0.1	0.007 \pm 0.003	4.2	7.00
GOP0.5	0.041 \pm 0.001	24.6	8.20
GOP1	0.134 \pm 0.009*	80.4	13.40*
GOP1.5	0.18 \pm 0.015*	108.0	12.00*

3
4

1 **Table 3.** DLS particle size analysis after incubation in cell culture medium and DI water for 1
2 and 48 h. * p -value < 0.005 compared to the particle size after 1 h incubation.

Sample	Effective diameter (nm) in DMEM		Effective diameter (nm) in deionized water	
	After 1h incubation	After 48h incubation	After 1h Incubation	After 48h incubation
GOP0.1	110±2.2	119±9.2	98±0.7	119±9.2
GOP0.5	132±9.3	140±11.2	127±4.3	140±11.2
GOP1	188±8.1	196±8.5	172±11	196±8.5
GOP1.5	388±33	> 1µm*	330±14	797±112*

3

4

5

6

7

8

9



10

11


12

13


14




96x116mm (300 x 300 DPI)




61x46mm (300 x 300 DPI)




57x40mm (300 x 300 DPI)




58x42mm (300 x 300 DPI)




53x35mm (300 x 300 DPI)




102x130mm (300 x 300 DPI)




55x39mm (300 x 300 DPI)





65x53mm (300 x 300 DPI)



82x85mm (300 x 300 DPI)



168x354mm (300 x 300 DPI)



61x46mm (300 x 300 DPI)